The FDA on September 10, 2025, approved KOSELUGO® granules and capsules for pediatric patients 1 year of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable Plexiform Neurofibromas (PN). FDA previously approved KOSELUGO® capsules for pediatric patients 2 years of age and older with NF1 who have symptomatic, inoperable PN. KOSELUGO® is a product of AstraZeneca Pharmaceuticals LP.
Bottom Ad
Advertisement
Subscribe
